Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
about
HDL particle number and size as predictors of cardiovascular diseaseCholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeysThe HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?CETP inhibitors and cardiovascular disease: Time to think again.Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.Markers of Systemic Inflammation and Apo-AI Containing HDL Subpopulations in Women with and without DiabetesA vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit.Reverse cholesterol transport is elevated in carboxyl ester lipase-knockout miceEffects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adultsCholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis.Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?Molecular regulation of HDL metabolism and function: implications for novel therapies.Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.Future therapeutic directions in reverse cholesterol transport.Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase IIThe inhibition of cholesteryl ester transfer protein: a long and winding roadEffects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.Torcetrapib/atorvastatin combination therapy.Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence.High-Density Lipoprotein - A Hero, a Mirage, or a Witness?Inhibitors of cholesteryl ester transfer protein--a new approach to coronary artery disease.Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targetsTherapeutic use of the high-density lipoprotein protein and peptides.Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.Thematic review series: patient-oriented research. What have we learned about HDL metabolism from kinetics studies in humans?High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease.CETP inhibition in cardiovascular risk management: a critical appraisal.High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease.Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- miceIn vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption.Viability of developing CETP inhibitors.Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis.High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapyDose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism.Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?Anacetrapib: hope for CETP inhibitors?Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
P2860
Q26779287-93A380D8-2D91-4441-97D1-93F982947879Q33590777-C490A2C9-21EA-4EEA-B1DD-7D8B2A86CD08Q33867662-351CCEF3-BF0F-4DA2-AF3B-502EDD827B70Q33993233-827632DC-307B-496B-9EC0-6D240FC93F64Q34109100-046643D4-3DCF-482A-B817-6DD42F8F5A35Q34155049-802BFFAE-B426-45DF-8615-D57B3CD919E7Q34203358-E56D77F8-6E1F-41C6-97B1-8B6CE9E59A69Q34653513-92E6C635-2193-401D-8A11-B2528CAAA43EQ34682311-E0D967EB-55BE-4FBB-8E58-B42FE81535D3Q34823459-39411F72-0C95-4590-93D9-9BBE1F7098DAQ34948139-A4914417-564D-4605-A00E-0117F7244211Q35049058-473A1EB0-7FAC-4655-9A76-DE986052D82AQ35191066-D8056BFC-AF9C-464C-AC02-876FF80E5C79Q35836143-0E11D0A1-0286-45ED-97F4-BBA752B6BBC6Q35860010-500EB477-5465-41D5-9C0A-9F8E0665ECD3Q35860767-4C3A462E-DE1E-424F-A672-CA798339EBF5Q35958413-93C3F186-D37A-46E4-93D5-783FBE8EDBE6Q35958491-B8912447-C2D5-48B9-868D-1467A5240E53Q36265996-B7D8B215-62B6-4D6B-8DA6-F7E4E3BDDC38Q36314862-CC33E475-F2BF-4EB0-B8FE-DFC44DD2614AQ36344712-6440B75C-55BE-4316-8609-B556BB0BAB95Q36376429-BFCFB3AE-C91B-410B-9646-B6C91FC7B6D3Q36383197-83D798C3-417B-4489-8803-E2BF5203B8EEQ36407298-B172B22F-3BD6-4163-AF92-EDA3D4BDF644Q36422727-C77A33D4-770E-4493-9B6B-9599CEC7061EQ36473656-1908A225-0586-45EB-9ED2-7EE94F408D0CQ36539475-E99771A6-96C7-448D-9C1B-50F8E2866826Q36705260-6D4294B2-9553-4CBA-AAA7-8A14966A32AAQ36766976-DBB6DD32-1605-4F86-9DE9-51C2C1D53788Q37013499-E681FEDA-6E1D-41F7-88AE-FE48EB767745Q37163010-3F5A42C3-E6C3-4840-B5B1-519179C9695FQ37163072-2BA62821-6380-466E-8FBB-4F5F284698ACQ37165682-94CD0916-2644-428A-84FE-60AE79C3389FQ37239358-F4FE7FFE-7311-4BFA-A79B-EF37D00D0CF8Q37254454-D92F06B4-AF2E-449B-98D0-C2F82C447AE6Q37311118-A00AA6D2-F2AE-450A-A168-4339CFF5EA38Q37340732-4353B304-C6D7-4D64-AF2B-2CF67E952A24Q37707402-D5C66405-45D7-4CB2-BC80-4654B7B333D8Q37734553-A21B1BF7-0C15-4543-B9A6-133CEEE26315Q37774393-4E317B62-9C36-4475-BA86-B64589DD2B5C
P2860
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Effects of cholesteryl ester t ...... m, and fecal sterol excretion.
@ast
Effects of cholesteryl ester t ...... m, and fecal sterol excretion.
@en
type
label
Effects of cholesteryl ester t ...... m, and fecal sterol excretion.
@ast
Effects of cholesteryl ester t ...... m, and fecal sterol excretion.
@en
prefLabel
Effects of cholesteryl ester t ...... m, and fecal sterol excretion.
@ast
Effects of cholesteryl ester t ...... m, and fecal sterol excretion.
@en
P2093
P2860
P1476
Effects of cholesteryl ester t ...... sm, and fecal sterol excretion
@en
P2093
Andres G Digenio
Bela F Asztalos
Bo Angelin
Chorthip Nartsupha
Daniel J Rader
Ernst J Schaefer
Francine K Welty
James P Mancuso
John S Millar
Margaret E Brousseau
P2860
P304
P356
10.1161/01.ATV.0000161928.16334.DD
P577
2005-03-10T00:00:00Z